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ABSTRACT 
 
Soft-tissue sarcomas (STSs) constitute a heterogeneous group of rare but aggressive  
tumors that originate from mesenchymal cells in almost any part of the body. 
Gastrointestinal stromal tumor (GIST), located in the gastrointestinal tract, is the most 
common type of STS. The aim of this thesis was to evaluate markers for development 
of progressive disease in highly malignant STS; moreover to assess the impact of 
adverse drug reactions and surgical margins on outcome for patients with GIST. 
 
Paper I. We evaluated 101 patients with high-grade STS for known and suggested 
prognostic markers, particularly the insulin-like growth factor type 1 receptor (IGF-
1R). A significant association was seen between high expression of IGF-1R and 
favorable outcome. Furthermore, large tumor size, occurrence of necrosis, high mitotic 
count, intralesional surgery, deep location and microvessel density were all 
significantly associated with poor outcome, whereas no association with outcome was 
found for either malignancy grade 3 or 4, infiltrative growth pattern, vascular invasion 
or any of the remaining immunohistochemical markers Ki67, p53, p27 or Bcl-2. 
 
Paper II. In 50 patients with highly malignant STS from the same series as Paper I we 
evaluated the prognostic role of ezrin, a protein involved in metastatic spread of cancer 
cells. Positive expression of ezrin by immunohistochemistry was found in half of the 
cases and this finding was significantly associated to death from or with disease as well 
as to development of metastasis. 
 
Paper III. The application of surgery and the tyrosine kinase inhibitor imatinib in the 
treatment of GIST has led to dramatically prolonged survival. However, imatinib is 
associated with frequent side-effects of variable severity. In a retrospective review of 
medical records from 75 patients who had received imatinib, we correlate side-effects 
to outcome, and found that moderate to severe or life-threatening toxic reactions were 
registered in 30 patients. Most of the side-effects occurred early. For the 34 patients 
with metastatic or recurrent GIST, presence of side-effects and female gender were 
associated with longer recurrence-free survival. 
 
Paper IV. Surgery is the main and only curative treatment for GIST. Complete surgical 
resection with microscopically negative margin (R0) is widely regarded as a 
prerequisite for intended curative treatment. We divided the patients on the basis of the 
surgical resection margin, as with other STSs, into wide, marginal or intralesional 
margin at surgery or referral and retrospectively correlated this to outcome. 
Local/peritoneal recurrence was diagnosed in 2 of 40 GISTs with wide margins, in 7 of 
24 GISTs with marginal margins, and in 13 of 19 GISTs with intralesional surgery. 
Cox regression analysis showed that a wide surgical margin is of significant prognostic 
importance independently of size and site. 
Furthermore, we analyzed the incidence of infiltrative growth pattern and its correlation 
to surgery and outcome. We found that 64% of GISTs had infiltrative growth and that 
this was significantly correlated to recurrent disease. However, there were no 
correlations to surgical margins. 
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1 INTRODUCTION 
 
The sarcoma entity constitutes a group of tumors that originate from mesenchymal cells 
in the connective tissue. The disease is rare and accounts for only approximately 1-2% 
of all malignant tumors (Ferrari, Sultan et al. 2011; Mastrangelo, Coindre et al. 2012; 
Stiller, Trama et al. 2013). Mesenchymal cells occur all over the body and therefore 
these tumors can occur in nearly all anatomical locations. Sarcomas are grossly divided 
into skeletal sarcomas and soft tissue sarcomas (STS); the latter group is more common 
than the former (Fletcher C.D.M. 2006; Stiller, Trama et al. 2013). The World Health 
Organization (WHO) classification recognizes more than 50 different entities of STS, 
all with more or less variable clinical, prognostic and therapeutic features (Fletcher 
C.D.M. 2006; Gatta, van der Zwan et al. 2011). The increased identification of specific 
molecular genetic alterations associated with certain types of sarcoma has improved 
diagnostic classifications and the understanding of factors influencing the success of 
conventional treatment. Targeted therapy based on the underlying molecular 
abnormality is presently applied to some types of sarcoma and such therapies are also 
in various phases of development for several other types (Cassier, Labidi-Galy et al. 
2011). The introduction of targeted therapies has tremendously improved the outcome 
for certain groups of sarcoma patients and ongoing developments are expected to 
continuously improve the therapeutic options (Floris, Wozniak et al. 2013). Moreover, 
the need for lengthy, sometimes life-long, medical treatment calls for increased 
attention to secondary issues such as side-effects and development of drug resistance. 
Another key research issue is to define biomarkers that can identify the subset of 
patients who would benefit most from a particular treatment. There is also a demand for 
improved understanding of factors influencing the success of conventional treatment 
such as surgery. 
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1.1 SOFT TISSUE SARCOMA (STS) 
 
1.1.1 Occurrence 
 
Since sarcomas may occur in any anatomic site of the body and are differentiated into 
many subtypes, the true incidence of any one subtype is probably underestimated. 
Using large population-based registries, the annual incidence of only STS is estimated 
to 4.7-5.6 per 100,000 persons (Ferrari, Sultan et al. 2011; Mastrangelo, Coindre et al. 
2012; Stiller, Trama et al. 2013). In the RARECARE compilation of rare cancers in 
Europe, 84% of sarcoma cases were STSs and 14% were bone sarcomas (Stiller, Trama 
et al. 2013). Annual incidence rates increase with age, starting from 0.9 per 100,000 
in children under 10 years and rising more dramatically after the age of 30 years to 
18.2 per 100,000 among individuals over 70 years (Ferrari, Sultan et al. 2011). 
Compared to other cancers, sarcomas occur more frequently in young adults and 
adolescents (Burningham, Hashibe et al. 2012). Overall, STSs account for 
approximately 7% of all pediatric malignancies and 20% of all pediatric solid 
malignant tumors but only constitute 1.5 % of all malignancies in adults (Clark, Fisher 
et al. 2005; Fletcher C.D.M. 2006; Stiller, Trama et al. 2013).  
 
Based on available data, an intra-abdominal location is most common (incidence of 
about 1.1-1.5 per 100,000), followed by the lower extremities (0.8-1.2), the trunk wall 
(0.54-0.77), the upper extremities (0.37-0.54) and retroperitoneum (0.2-0.76) (Nilsson, 
Bumming et al. 2005; Tryggvason, Gislason et al. 2005; Stiller, Trama et al. 2013). 
Except for a female predominance for leiomyosarcoma and soft tissue alveolar 
sarcoma, the incidence is similar or slightly higher among men. One third of tumors 
located in the trunk wall and extremities are superficial, with an average size of 5 cm; 
the remaining two thirds are deep-seated with an average size of 9 cm (Fletcher C.D.M. 
2006).   
 
The overall survival for all persons diagnosed with any type of STS was reported to 
be 51% at 5 years, 38% at 10 years, and 30% at 15 years. Relative survival estimates 
were 57-62%, 55% and 51% at 5, 10, and 15 years, respectively. Patients under 50 
years of age at diagnosis had a better cancer-specific survival (about 88.8%) than 
older patients (40%). Overall and relative survival in gastrointestinal stromal tumor 
(GIST) were 59% and 68%, respectively, while patients diagnosed with 
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retroperitoneal sarcoma had relatively poor outcome with 5-year overall survival of 
36-58% (Porter, Baxter et al. 2006; Ferrari, Sultan et al. 2011; Stiller, Trama et al. 
2013). 
 
The most common STS is GIST, followed by liposarcoma, leiomyosarcoma and 
synovial sarcoma. The age-related incidence varies between the entities. 
Leiomyosarcoma and liposarcoma are the most common histopathological entities in 
the elderly, whereas synovial sarcoma mostly occurs in young adults and embryonal 
rhabdomyosarcoma almost only in children. Lipoma is the most common benign form 
of soft tissue tumor (Fletcher C.D.M. 2006; Ferrari, Sultan et al. 2011; Mastrangelo, 
Coindre et al. 2012). 
 
1.1.2 Signs and symptoms 
As a rule, patients with STS have no or very few symptoms from the tumor. Symptoms 
such as pain, tenderness or loss of function are rarely present and the person typically 
feels perfectly healthy. The only signs of a possibly malignant tumor are bleeding or 
the presence of a lump accidentally noted by the patient. That is why these tumors are 
often misinterpreted as benign lesions and left without further notice by both patients 
and physicians. Consequently, a long interval may elapse before the patient is referred 
to a clinical center. In a study by Saithna et al, the median delay before referral was 70 
weeks; however, no significant difference in outcome was noted, except for patients 
with metastasis at diagnosis, who were referred earlier but had a worse prognosis from 
the start (Saithna, Pynsent et al. 2008). 
 
1.1.3 Etiology 
Only a few STS have an identifiable cause. Many studies have analyzed various 
potential risk factors for sarcoma development, for example radiation, infection, 
occupation, genetic predisposition and chemical exposure (e.g. herbicides) (Li and 
Fraumeni 1969; Serraino, Franceschi et al. 1992; Smith and Christophers 1992; 
Kogevinas, Kauppinen et al. 1995; Pollack and Mulvihill 1997; Hum, Kreiger et al. 
1998; Pearce, Hammal et al. 2007; Burningham, Hashibe et al. 2012). However, most 
of these studies have not found sufficient evidence for definite conclusions. 
Nevertheless, some definite risk factors have been identified. Acquired 
immunodeficiency resulting from treatment in transplant recipients or from HIV-
infection is associated with an increased risk of Kaposis sarcoma, where EBV and 
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HHV8 are the viruses of central importance (Kedes, Operskalski et al. 1996; Grulich, 
van Leeuwen et al. 2007). Radiation exposure in connection with radiotherapy is 
strongly associated with development of secondary sarcoma (Rubino, Shamsaldin et al. 
2005; Virtanen, Pukkala et al. 2006). (Burningham, Hashibe et al. 2012). 
 
Genetic predisposition has been identified in some situations, although less than might 
be expected from the relatively higher occurrence in children and adolescents. The Li-
Fraumeni’s syndrome was first recognized as associated with sarcoma predisposition 
(Li and Fraumeni 1969). This syndrome is associated with constitutional mutations of 
the TP53 gene and a high risk of osteosarcoma, STS, breast cancer and various other 
cancers (Burningham, Hashibe et al. 2012). More recently, constitutional mutations 
have been identified in a few patients with GIST in KIT and PDGFRA, which also 
show frequent somatic mutations in this disease. In addition, constitutional mutations 
occur in the neurofibromatosis type 1 gene (NF1) and the members of the succinate 
dehydrogenase complex (SDH) genes (Miettinen, Fetsch et al. 2006; Agaimy, Vassos et 
al. 2012; Miettinen, Killian et al. 2013; Oudijk, Gaal et al. 2013), suggesting a link to 
syndromes with other neuro-endocrine tumors.  
 
1.1.4 Histopathology and grading  
The histopathological diagnosis is made in accordance with the WHO Classification 
(Fletcher C.D.M. 2006). The most important variables in histopathologic malignancy 
grading include tumor size, depth, necrosis, and vascular invasion, as well as cellularity 
and cellular atypia (Engellau 2004; 2012). Malignancy grading is of importance in the 
treatment of all types of cancer, including sarcoma, in order to predict outcome and 
improve the treatment of each patient. Several grading systems of STS have been 
described, including the three-tier National Cancer Institute (NCI) system, the three-
tier French Federation of Cancer Centers (FNCLCC) system, the two-tier Memorial 
Sloan-Kettering Cancer Center (MSKCC) system and the four-tier system modified 
from Broder et al. The histological malignancy grading of STS used to date in 
Scandinavia is based on a four-tiered scale modified from Broder’s system (Goyanna, 
Torres et al. 1951; Angervall, Kindblom et al. 1986). Grade 1 and 2 are considered as 
low malignancy and grades 3 and 4 as high malignancy. The assessment is based on 
histopathological assessments of tumor cellularity, differentiation, mitotic rate, cellular 
atypia and amount of necrosis (Angervall, Kindblom et al. 1986). Although no grading 
system is universally accepted, high-grade histology, characterized by poor 
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differentiation, cellular pleomorphism, necrosis, and mitoses, has consistently 
emerged as a negative prognostic factor for patients with STS, irrespective of which 
grading system is used. 
 
Prognostic factors used for STSs are currently based on clinical and histopathological 
characteristics such as morphological malignancy grade, size, site, depth, necrosis, 
vascular invasion and growth pattern, all of which are significant factors for outcome. 
Vascular invasion, growth pattern and tumor necrosis are also strong prognostic factors 
for metastases (Mandard, Petiot et al. 1989; Engellau, Bendahl et al. 2005). The TNM 
classification system is commonly applied to STS, as detailed in Table 1.  
 
Table 1. TNM classification of sarcomas 
Parameter / Sub-  
Classification classification Criteria 
Primary tumor (T)  
  TX  primary tumor cannot be assessed  
  T0  no evidence of primary tumor  
  T1  tumor < 5 cm in greatest dimension 
 T1a superficial tumor* 
 T1b deep tumor 
  T2  tumor > 5 cm in greatest dimension 
 T2a superficial tumor 
 T2b deep tumor 
Regional lymph nodes (N)  
  NX  regional lymph nodes cannot be assessed 
  N0  no regional lymph node metastasis 
  N1  regional lymph node metastasis 
Distant metastasis  
  M0  no distant metastasis 
  M1   distant metastasis 
   
Modified from NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma 
at http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. 
 
1.1.5 Prognosis 
The 5-year overall survival for STS patients is about 57% to 62% (Ferrari, Sultan et al. 
2011; Stiller, Trama et al. 2013). The prognosis for patients with STS is influenced by 
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so many factors that no grading system has been universally accepted. Irrespective of 
which grading system is used, patients with high-grade tumors are at significant risk 
of distant recurrence, and as many as 50% of them die of their disease. Conversely, 
patients with low-grade STS have an excellent prognosis, with 5-year survival rates 
of 85% or more (Kattan, Leung et al. 2002; Canter, Qin et al. 2008). Retroperitoneal 
tumors are generally much larger at diagnosis and this group has a poorer prognosis 
(36-58%). Metastases are detected in 36% of STS patients at diagnosis or during 
follow-up (Engellau, Bendahl et al. 2005). Approximately 11% of all STS patients have 
detectable metastasis already at diagnosis, most commonly in the lungs, and the 5-year 
survival in this group is only 14%. The occurrence of local recurrence depend on 
factors such as the local treatment. In a report by Engellau et al. local recurrence 
occurred in 32% of patients with inadequate local treatment as compared to 15% of 
those with adequate local treatment (Engellau, Bendahl et al. 2005). 
 
1.1.6 Treatment 
Treatment of STS follows guidelines from the Scandinavian Sarcoma Group 
(http://www.ssg-org.net/treatment-protocols-and-recommendations, SSG XVII, SSG 
XX and SSG XIX), and the European Society for Medical Oncology (ESMO; 
Guidelines for soft tissue sarcoma ESMO) (2012). In order to provide adequate 
expertise in surgical and adjuvant therapy, patients with STS are best treated in 
specialized multidisciplinary centers, and a histopathological review should always be 
done by an expert on STS (Clasby, Tilling et al. 1997). Surgery and radiotherapy are 
classical treatments for sarcoma patients. Surgery with a wide margin is the main 
treatment of STS, as has been known for a long time (Bowden and Booher 1958). STSs 
grow spherically along tissue planes and are surrounded by a false capsule of 
compressed surrounding tissue. Malignant cells penetrate this capsule and simple 
removal leaves microscopic disease and a high risk of recurrence (Bowden and Booher 
1958; Gerrand, Wunder et al. 2001). For patients with low-grade sarcoma, where the 
prognosis is fairly good, surgery alone is the standard treatment, whereas in high-grade 
sarcoma, where the prognosis is poor, a decision has to be made on whether or not the 
patient should receive adjuvant therapy. Based on a study from Roswell Park Cancer 
Institute of sarcoma patients treated between 1979 and 1998, radiotherapy was 
recommended for all patients with a margin smaller than 10 mm. In that study, the 
smallest microscopic margins were divided into three categories: at least 10 mm, 1–9 
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mm and 0 mm, which yielded 5-year local control rates of 84, 58 and 58%, respectively 
(McKee, Liu et al. 2004).  
 
In addition, chemotherapy and therapies directed at molecular tumor features are 
increasingly applied. Chemosensitivity varies between the types of STS and is 
influenced by tumor grade, timing of metastatic disease and patient performance. 
Neoadjuvant therapy is increasingly used and may improve prognosis in high-risk cases 
(Grobmyer, Maki et al. 2004). Trabectidin (Yondelis, Swedish Orphan Biovitrum), a 
natural product from the marine tunicate Ecteinascidia turbinate, is a new agent that has 
been found to have an effect in advanced disease resistant to conventional cytotoxic 
drugs (Yovine, Riofrio et al. 2004). 
 
1.1.7 Surgical margin 
A definition of surgical margin has been proposed by the Scandinavian Sarcoma 
Group. The margin should be assessed at surgery and by macroscopic and microscopic 
pathological examination. The poorest margin is most important, i.e. the part of the 
specimen where the tissue coverage is poorest (qualitatively and quantitatively). This is 
the area where the pathologist should record the type of tissue (e.g. fat, connective 
tissue) and the thickness (mm) of tissues covering the tumor. Positive margin refer to 
situations where the surgery was not radical and all tumor tissue was not removed. Two 
types of positive margin are described:  
Gross tumor left: The tumor is transected during the operation and macroscopic tumor 
tissue is left. This situation is reported by the surgeon.  
Intralesional: Microscopic tumor tissue is seen at the resection border (reported by the 
pathologist) or leakage of fluid/tissue from the tumor into the wound occurs during 
surgery (reported by the surgeon). 
 
When the surgical procedure successfully removes the entire tumor mass, this is 
referred to as negative margin. Two types of negative margin are defined: marginal and 
wide. The decision as to whether or not the margin is negative, i.e. tumor-free, lies with 
the pathologist. In the case of a negative margin, the pathologist reports the shortest 
distance (in mm) between the tumor and the resection border in fat, muscle or loose 
areolar tissue in an area where there is no fascia between the tumor and the resection 
border. A fascia unengaged by the tumor is considered to be sufficient for a wide 
margin irrespective of the distance between tumor and fascia. A total myectomy with 
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the tumor completely surrounded by unengaged fascia needs no measurements and is 
classified by the surgeon as a wide margin. The distinction between a marginal and a 
wide margin is made by the surgeon and is based on the combined information from 
surgery and histopathological examination. 
Marginal margin: The closest margin is outside but near the tumor in one or more 
places (irrespective of how much healthy tissue is included elsewhere) or all round the 
tumor (shelling out). Microscopically, the margin is negative all round the tumor 
(otherwise the margin is intralesional), but tumor cells may be present only millimeters 
from the margin. 
Wide margin: There is a cuff of healthy tissue all round the tumor. Unengaged fascia is 
considered to constitute a cuff regardless of the thickness of tissue between the tumor 
and the fascia. A cuff of fatty or muscular or loose areolar tissue must be at least 10 mm 
thick as measured at the histopathological examination to qualify as a wide margin. 
Definitions as recommended by the Scandinavian Sarcoma Group (http://www.ssg-
org.net/treatment-protocols-and-recommendations; Centralized Registration of 
Sarcoma Patients in Scandinavia, SSG VII:4). 
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1.2 GASTROINTESTINAL STROMAL TUMOR (GIST) 
Gastrointestinal stromal tumor (GIST) was shown in the 1980s to be a separate entity 
(Mazur and Clark 1983; Miettinen 1988). These tumors had previously been diagnosed 
as leiomyoma, leiomyoblastoma, schwannoma or leiomyosarcoma. In 1998, Hirota et 
al. found gain-of-function mutations of the KIT gene in GISTs and proposed that 
GISTs may originate from the interstitial cells of Cajal. The c-kit receptor encoded by 
the KIT gene was suggested to be a target for diagnosis and treatment (Hirota, Isozaki 
et al. 1998; Kindblom, Remotti et al. 1998; Nakahara, Isozaki et al. 1998). The 
breakthrough in the knowledge of molecular mechanisms and new molecular targeted 
therapies have resulted in effective systemic treatment with tyrosine kinase inhibitors 
(TKIs) and a dramatically improved outcome for patients with recurrent or metastatic 
disease, as well as prolonged the time to recurrence and overall survival in highly 
malignant GIST (Verweij, Casali et al. 2004; Blanke, Demetri et al. 2008). Many novel 
agents are now being tested in the treatment of GIST. Nevertheless, the majority of 
patients are treated with surgery alone, giving a 15-year survival rate of 60% for 
patients with primarily operable tumors. 
 
1.2.1 Occurrence 
GIST is by far the most common mesenchymal tumor of the gastrointestinal tract and 
is assumed to be the most common mesenchymal tumor whatsoever (Mastrangelo, 
Coindre et al. 2012; Stiller, Trama et al. 2013). The annual incidence of clinically 
detected GIST in the Western region of Sweden was estimated to be 15 cases per 
million and the prevalence to be 129 per million (Figure 1) (Nilsson, Bumming et al. 
2005). In two population-based series from Iceland and Italy, the annual incidence of 
GIST was 11 and 7 per million, respectively (Tryggvason, Gislason et al. 2005; 
Mucciarini, Rossi et al. 2007). GIST is slightly more frequent in males except for 
pediatric GIST, where females predominate (Janeway and Pappo 2012; Joensuu, 
Vehtari et al. 2012). The median age at diagnosis is 63 to 65 years, but GIST occurs 
at all ages. GIST can arise throughout the gastrointestinal tract from esophagus to 
rectum, most commonly in the stomach (55%), followed by the small intestine (35%) 
and rectum (5%). Colon and esophagus are rare locations (less than 5%). Rarely, 
GIST arises outside the gastrointestinal tract but inside the abdominal cavity 
(Janeway and Weldon 2012; Joensuu and DeMatteo 2012). 
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Figure 1.	  Incidence of GIST in a Western Swedish population (n = 259). Modified 
from Nilsson et al. (Nilsson, Bumming et al. 2005). 
 
1.2.2 Signs and symptoms 
As in other sarcomas, GIST usually gives sparse and/or late symptoms. Bleeding 
from the GI-tract, due to ulcer in the mucosa at the site of the tumor, is the most 
common symptom, seen in about 50%. Other symptoms are mostly dependent on the 
site of origin; abdominal pain/discomfort represents about 20% and obstruction as 
initial symptom is seen in about 10% of the patients. Fatigue is rare but may occur in 
cases with large tumors. The median size of the tumor at diagnosis is 5-7 cm but can 
be up to 30-40 cm (Joensuu, Fletcher et al. 2002; Nilsson, Bumming et al. 2005; 
Joensuu and DeMatteo 2012). 
 
1.2.3 Histopathology, grading and prognosis  
The diagnosis is based on morphology and immunophenotyping, and in difficult cases 
also on mutation analysis. Morphologically GIST is typically characterized by a 
cellular tumor with either spindle cells (70%), epitheloid cells (15%) or mixed cell 
forms (15%), however pleomorphic cells also occur (Miettinen 1988). 
Immunohistochemistry usually show positivity for CD117, DOG-1 and CD34, and 
sometimes also for smooth-muscle actin (SMA) (Table 2) (Sarlomo-Rikala, Kovatich 
et al. 1998; Miettinen, Sobin et al. 2000; West, Corless et al. 2004; Kang, Jung et al. 
2010). Mitotic count determined as mitotic figures per 50 high power fields (HPFs) and 
the size of the tumor are both important for prognostic classification of GIST (Fletcher, 
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Berman et al. 2002; Miettinen, Majidi et al. 2002; Joensuu 2008; Miettinen and Lasota 
2011). 
Table 2. Markers for immunohistochemical characterization of GIST. 
Target protein  
Symbol Name Finding in GIST 
c-kit Stem cell factor receptor 88-97% positive cases 
DOG1 Discovered on GIST-1 87-97% positive cases 
CD34  Hematopoietic progenitor cell antigen 60-70% positive cases 
α-SMA Alpha smooth muscle actin 30-40% positive cases 
S-100 S100 protein 5% positive cases 
Desmin  Desmin <5% positive cases 
Ki-67  Antigen identified by the antibody Ki-67 MIB-1 proliferation index <1-80% 
  
 
No GIST can be regarded as truly benign, although patients with small tumors of low 
proliferation index have the same survival as the normal population. Based on pooled 
cohorts of patients with surgically completely removed GISTs who had not received 
neoadjuvant or adjuvant treatment, recurrence-free survival after surgery was 
estimated to 60%. Few recurrences occurred after 10 years of follow-up. Tumor size, 
high mitotic count, non-gastric location, ruptured tumor and male gender were found 
to be significant, independently adverse risk factors (Joensuu, Vehtari et al. 2012). In 
contrast, for patients with high-risk GIST, the 3-year survival was only about 20-30% 
and the median survival for patients with advanced disease was 18 months 
(Dematteo, Heinrich et al. 2002). Miettinen et al. have published several studies on 
the risk of progressive disease for patients with GIST at different sites (Table 3). 
Interestingly, the risk for malignant behavior was lower in the stomach but differed 
markedly depending on where in the stomach the tumor was located. The highest risk 
of progressive disease was seen for GIST in the cardia region (53%), somewhat lower 
in fundus (36%) and markedly lower in antrum (8%) (Miettinen, Sobin et al. 2005; 
Miettinen and Lasota 2006; Miettinen, Makhlouf et al. 2006). 
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Table 3. Risk of progressive disease in operable GIST based on follow-up data 
Tumor size  Mitotic count              Risk of progressive disease   
(cm) per 50 HPF Stomach Duodenum Jejunum/Ileum Rectum 
 ≤ 2.0  ≤ 5 0% - - - 
 2.1 - 5.0  ≤ 5 2% 4% 8% 9% 
 5.1 - 10.0  ≤ 5 4% 24% 25% - 
 > 10.0  ≤ 5 12% 52% 52% 57% 
      
 ≤ 2.0  > 5 0% -  50% 54% 
 2.1 - 5.0  > 5 16% 73% 75% 52% 
 5.1 - 10.0  > 5 55% 85% 86%  - 
 > 10.0  > 5 86% 90% 90% 71% 
Modified from Miettinen M, Lasota and Sobin 2005-2006   
HPF = High power field     
 
Following the introduction of imatinib, the prognosis of advanced GIST has changed 
dramatically. The response rates for patients with unresectable, metastatic or recurrent 
GIST are 50-70%. The survival for this group has been prolonged to a median 
progression-free survival of 18-20 months (Miettinen, Makhlouf et al. 2006; 
Rajendra, Pollack et al. 2013). In a follow-up study of a randomized phase II B2222 
trial, in which patients with recurrent or unresectable GIST were followed for a 
median of 40 months (range 2.5-103) under imatinib treatment, the median 
progression-free survival was 89 months and the overall survival for 8 years was 
67%. In one subgroup (17.7%), the patients survived with continuous imatinib 
treatment for more than 9 years (Saito, Nakata et al. 2013). 
 
Several systems for risk stratification have been developed to achieve individualized 
treatment and follow-up by assessing the prognosis of the individual patient (Fletcher, 
Berman et al. 2002; Nilsson, Bumming et al. 2005; Miettinen and Lasota 2006). In 
Scandinavia we mainly use the NIH risk categories modified by Joensuu et al. to 
include tumor rupture (Joensuu 2008) (Table 4). 
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Table 4. Definition of risk categories proposed by Joensuu et al.  
Risk  Tumor size Mitotic index Tumor  
Category (cm) (per 50 HPF) site 
Very low risk  ≤ 2.0  ≤ 5 Any 
Low risk  2.1 - 5.0  ≤ 5 Any 
Intermediate risk  2.1 - 5.0  ≤ 5 Gastric  
  ≤ 5.0  6-10 Any 
  5.1 - 10.0  ≤ 5 Gastric 
High risk  Any  Any Tumor rupture 
  > 10.0  Any Any 
  Any  > 10 Any 
  > 5.0  > 5 Any 
  ≤ 5.0  > 5 Non-gastric 
   5.1 - 10.0  ≤ 5 Non-gastric 
(Joensuu 2008)    
 
Size and proliferation are the most important prognostic factors in GIST. In general, 
large tumors and tumors with high mitotic count (mitosis per 50 HPF) have a high 
risk of recurrence (Fletcher et al., 2002). However, follow-up data show that the site 
is also of importance. For tumors in the stomach the prognosis appears to be 
prognosis and proliferation is more important than size, while tumors in the small 
intestine and rectum mostly have a worse outcome (Miettinen and Lasota, 2006). 
Tumor rupture has also been shown to be significantly correlated to recurrence and 
overall survival (Rutkowski, Nowecki et al. 2007; Hohenberger, Ronellenfitsch et al. 
2010). Tumor rupture has therefore been included in the modified NIH criteria 
proposed by Joensuu et al. (Table 4)(Joensuu 2008). 
 
1.2.4 Molecular Pathology 
GISTs usually express mutations in the tyrosine kinase receptor genes KIT or 
PDGFRA. These oncogenes encode the transmembrane glycoproteins c-kit (CD117, 
stem cell factor receptor) and platelet-derived growth factor receptor alpha (PDGFRA), 
both members of the type III tyrosine kinase receptor family. c-kit and PFGFRA are 
activated by binding of their respective ligands, the stem cell factor and PDGFA, to the 
extracellular region. These serve as binding sites for various signaling proteins, leading 
to phosphorylation cascades with activation of signaling substrates that regulate cell 
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proliferation, adhesion, motility, survival and differentiation of hematopoietic stem 
cells, mast cells, melanocytes, germ cells and interstitial cells of Cajal. Expression of c-
kit can be detected in GIST, but also in other tumors such as small cell lung carcinoma, 
melanoma and seminoma.  
 
Mutations of KIT and PDGFRA in GIST are activating (so-called gain-of-function 
mutations), leading to ligand-independent dimerization, autophosphorylation and 
activation of downstream signaling pathways (Hirota et al., 1998). The majority of KIT 
mutations are located within exon 11 (Hirota, Isozaki et al. 1998; Tabone, Theou et al. 
2005; Lasota and Miettinen 2008; Liegl-Atzwanger, Fletcher et al. 2010). KIT exon 11 
mutations are found in approximately 60-70% of all GISTs, and exon 9 mutations are 
found in 10%, whereas other mutations are rare; exon 13 mutations in 1%, and exon 17 
mutations in <1% of cases. Mutant KIT supports growth by activation of downstream 
signaling pathways, e.g. the MAPK P13K-AKT and STAT3 pathways. The P13K-AKT 
pathway seems to be the most important, since inhibitors of P13K have a better effect 
on reducing proliferation and inducing apoptosis. About 8% of GISTs exhibit 
mutations in PDGFRA, exon 12, 14 or 18 and there is an extensive functional overlap 
between c-kit and PDGFRA. As in c-kit has mutated PDGFRA a kinase activity 
despite absence of its ligand. The activated downstream pathways are overlapping in 
PDGFRA and KIT mutant GIST (Heinrich, Corless et al. 2003; Corless, Barnett et al. 
2011). 
 
Almost all GISTs express mutated KIT, causing a ligand independent activation of c-
kit. Mutation analysis is a useful tool in the management of GIST patients and should 
be done whenever possible. The results may be needed in the diagnostic setting and 
may be used as prognostic markers, sometimes influencing the choice of treatment. The 
location of mutations has an impact on the outcome in untreated patients and different 
mutations are also associated with the response to imatinib treatment. GISTs with KIT 
exon 11 deletions have a higher rate of progressive disease compared to those with 
point mutations (22% vs. 0%). In addition, KIT exon 13 or 17 mutations are often 
detected in recurrences and cases with resistance to imatinib treatment (Corless, Barnett 
et al. 2011). PDGFRA mutations are not significantly correlated to prognosis (Heinrich, 
Corless et al. 2003; Andersson, Bumming et al. 2006; Corless, Barnett et al. 2011). 
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The 5 to 10% of GISTs that lack mutations in either KIT or PDGFRA have been named 
wild-type GIST (wtGIST) (Heinrich, Corless et al. 2003; Corless, Fletcher et al. 2004). 
These wtGIST are otherwise clinically identical and express high levels of c-kit. 
However, recent studies have described that wtGISTs are a heterogeneous group 
displaying various oncogenic mutations, e.g. in BRAF (Corless, Barnett et al. 2011). 
Furthermore, defects in the succinate dehydrogenase (SDH) complex have been 
reported in wtGIST. IGF-1R expression was detected in 89% of SDH-deficient GISTs 
but in less than 1% of SDH-positive GISTs. The latter group was characterized by 
mutations in KIT or PDGFRA and occurred in older patients. SDH-deficient tumors 
had lost the expression of SDH subunit B, resulting in inactivation of the SDH-
complex. This subtype of GISTs has only been identified in the stomach and mostly in 
children or young adults (Lasota, Wang et al. 2013; Miettinen, Killian et al. 2013). 
 
1.2.5 Treatment 
Generally, treatment of GIST should follow guidelines issued by SSG (http://www.ssg-
org.net/treatment-protocols-and-recommendations; SSG XVII) and ESMO guidelines 
for GIST (2012). 
 
Presurgical evaluation 
A reliable Diagnosis before treatment is mandatory, in particular if the tumor is large 
and the surgical procedure is expected to be complex or if neoadjuvant treatment is 
considered. Fine-needle aspiration biopsy is the method of choice for preoperative 
diagnosis and, since about 60% of all GISTs are located in the stomach, endoscopic 
ultrasound (EUS) is preferable if possible. With EUS, both fine-needle aspiration 
biopsy and core biopsy could be performed. Moreover, EUS has by itself a high 
diagnostic value, based on its ability to determine the localization within the ventricular 
wall (Fu, Eloubeidi et al. 2002; Kataoka, Kawai et al. 2012; Layfield and Wallander 
2012). Core-needle biopsy is rarely indicated and should be used only before 
neoadjuvant treatment, when mutation analysis is needed or if fine-needle aspiration 
gives insufficient information. Open biopsy should never be performed as this 
procedure will mimic tumor rupture and significantly influence the prognosis. 
 
For Anatomical evaluation of GIST, computed tomography (CT) is regarded as the 
standard modality that may be used for primary detection of a tumor, treatment 
decisions, planning for surgery, assessment of response and follow-up, and for 
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distinguishing the lesion from other malignancies (Buckley and Fishman 1998; 
Chourmouzi, Sinakos et al. 2009). Most commonly, the appearance is that of an 
exophytic tumor growing from the wall of the gastrointestinal tract, but GISTs may also 
appear as intramural masses or intraluminal polyps. The majority of GISTs appear to be 
well-defined lesions with varying attenuation. Larger lesions are often less distinctly 
demarcated, with invasion of adjacent structures. Areas of necrosis or hemorrhage are 
often seen (Levy, Remotti et al. 2003; Chourmouzi, Sinakos et al. 2009). 
 
For assessment of response to neoadjuvant treatment with TKIs, contrast-enhanced CT 
is routinely used. Response is usually seen as a rapid transition from a heterogeneously 
hyperattenuating pattern to a more homogeneously hypoattenuating pattern, often 
followed by a reduction of tumor size and extensive cystic changes. In the follow-up, 
detection of a focal or a new solid lesion is often an early sign of progressive disease 
(Choi, Charnsangavej et al. 2004; Werewka-Maczuga, Osinski et al. 2011). 
 
Positron emission tomography combined with CT (PET/CT), using the radiotracer 18F-
fluoro-2-deoxy-D-glucose (FDG), is superior to conventional CT in some situations. 
PET is especially valuable when an early assessment is needed during neoadjuvant 
imatinib treatment.	  Like most malignant tumor cells, GIST cells normally have a high 
uptake of glucose. In response treatment with imatinib, a change in glucose uptake is 
detected early. FDG-PET/CT is also useful for distinguishing active tumor tissue from 
necrosing tissue, as well as for detecting metastatic or recurrent disease (Van den 
Abbeele and Badawi 2002; Stroobants, Goeminne et al. 2003; Yoshikawa, Shimada et 
al. 2012). 
 
Surgery 
Despite the introduction of effective molecular targeted therapy, which has 
dramatically changed the course for patients with highly malignant tumors, surgery is 
still the main treatment for non-metastatic GIST and the only curative option. Joensuu 
et al. conducted an observational cohort study based on pooled data from several 
published population-based series of patients with operable GIST without metastasis 
who did not receive adjuvant systemic therapy; only patients with GISTs that 
macroscopically were completely removed at surgery were included. In this study, the 
estimated 15-year recurrence-free survival after surgery alone was 60% (95% CI 56–
64). Most of the recurrences occurred within 5 years from diagnosis, a few recurrences 
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occurred after the first 10 years of follow-up and occasional cases were seen later 
(Joensuu, Vehtari et al. 2012).  
 
A complete surgical resection with histopathologically negative margin (R0) is 
commonly regarded as a prerequisite for potentially curative treatment (Ng, Pollock et 
al. 1992; Bucher, Egger et al. 2006; Rutkowski, Nowecki et al. 2007; Catena, Di 
Battista et al. 2012; Joensuu, Vehtari et al. 2012). A study by Ng et al. found that 
complete resection without tumor rupture was the only significant factor for overall 
survival, using multivariate analysis (Ng, Pollock et al. 1992). This is also partly 
supported by reports showing that tumor rupture is associated with a worse outcome 
(Ng, Pollock et al. 1992; Rutkowski, Nowecki et al. 2007; Hohenberger, Ronellenfitsch 
et al. 2010; Joensuu, Vehtari et al. 2012). Most recurrences occur in patients with 
ruptured tumor or within the high-risk group. In a study on patients treated for rectal 
GIST, Jakob et al. found that none of the patients with local recurrences during follow-
up had received preoperative imatinib and all had undergone local resection with 
positive resection margins (R1)(Jakob, Mussi et al. 2013). There is, however, still some 
uncertainty about surgical margins since some studies have shown that outcome does 
not differ significantly between R0 and R1 resection (DeMatteo, Lewis et al. 2000; 
McCarter, Antonescu et al. 2012). 
 
For STSs other than GIST, surgery is classified on the basis of resection margins as 
intralesional (equivalent to R1), and marginal or wide (equivalent to R1 resection) 
modified from Enneking et al. (Enneking, Spanier et al. 2003). This subgrouping of R0 
surgery is well established and has been shown to have prognostic significance in 
several studies where a resection margin of 2-3 cm has been suggested to provide good 
local control (Trovik, Bauer et al. 2000; Sampo, Tarkkanen et al. 2008). Although this 
classification has not been shown to be applicable in GIST, Paper IV in this thesis 
supports the necessity of complete resection margins, equal to R0, and indicates that 
wide surgical resection margins provide the best outcome.  
 
In conclusion, the main treatment for non-metastatic GIST is surgery, which should be 
planned and performed in accordance with surgery for other kinds of visceral and 
retroperitoneal sarcomas aiming to achieve R0 resection (Bumming, Ahlman et al. 
2006). Surgery may be performed by either traditional open or laparoscopic surgery as 
long as the oncological precautions are strictly observed and should if necessary 
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include adjacent organs that are adherent to the tumor. Since GIST almost never 
metastasizes through the lymphatics, lymph node resection is not indicated (Everett and 
Gutman 2008). 
 
Surgery in advanced, recurrent and metastatic disease 
Increasing evidence supports surgery in cases of advanced, metastatic or recurrent 
disease (Maehara, Chijiiwa et al. 2008; Zaydfudim, Okuno et al. 2012; Tielen, Verhoef 
et al. 2013). Surgery improves the overall survival compared to systemic therapy alone 
but 1- and 5-year overall survival rates are strongly associated with both preoperative 
response to TKI and R0 resection (Maehara, Chijiiwa et al. 2008; Zaydfudim, Okuno et 
al. 2012). Using neoadjuvant treatment of primary advanced GIST, Tielen et al. 
reported that downsizing of tumor was achieved in 52 of 57 patients who could be 
operated on with R0 resection without tumor rupture (Tielen, Verhoef et al. 2013). Six 
months of neoadjuvant treatment is recommended to avoid the occurrence of secondary 
mutations (Gold and Dematteo 2007). 
 
Treatment of advanced GIST 
In 2001 Joensuu et al. reported a patient who had been treated with the TKI STI571 
(Imatinib mesylate, Glivec) and had a complete metabolic response within one month 
(Joensuu, Roberts et al. 2001). This initial report lead to an amazing era of TKIs in the 
treatment of GIST. The Phase II study of imatinib [CSTI571B 2222] treatment of 147 
patients with recurrent or metastatic GIST resulted in partial response rates of 67% and 
66% for treatment with 400 mg/d and 600 mg/d, respectively. For patients with 
unresectable or metastatic GIST, the introduction of imatinib treatment has extended 
the median overall survival from 19 to 57 months. A follow-up study of the randomized 
phase II trial B2222 found that a subset of patients (almost 18%) had survived for more 
than 9 years with continuous imatinib treatment (Blanke, Demetri et al. 2008; Patel 
2013). Saito et al. reported even longer progression-free survival, 89 months, and 
overall survival at 8 years was 67%. The authors attribute this mainly to the intensive 
management of adverse events (Saito, Nakata et al. 2013).  
 
Imatinib is currently considered as the first-line systemic therapy in patients with 
metastatic or primarily non-operable disease. A daily dose of 400 mg is the standard in 
most cases (Demetri, von Mehren et al. 2002; Joensuu, Fletcher et al. 2002; Blanke, 
Rankin et al. 2008; Joensuu and DeMatteo 2012). The response to imatinib treatment is 
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best in patients with KIT exon 11 mutations (Heinrich, Corless et al. 2003), but patients 
with other mutations or wtGIST may also respond. A higher dose (800 mg imatinib) is 
recommended for patients with tumors harboring exon 9 mutations. This is based on 
the phase III European Organization for Research and Treatment of Cancer trial, where 
patients with exon 9 mutations had a superior progression-free survival when initially 
treated with a higher dose of imatinib (Debiec-Rychter, Sciot et al. 2006). 
Approximately 80% of GIST patients respond to treatment with imatinib; tumor 
volume decreases in about 50% and the remainder has stable disease. 
 
In most patients with advanced GIST who initially respond to imatinib, disease 
progression eventually occurs. The median time to progression exceeds 2 years. The 
maximum duration of response to imatinib is not yet known, but in some patients it is 
much longer than 5 years. The most common cause of acquired imatinib resistance is a 
second KIT mutation (Joensuu and DeMatteo 2012). Furthermore, about 15% of the 
patients have primary resistant tumors. In progressive disease, a fraction of patients 
respond to an increase in the dose to 600-800 mg daily or even higher (Blanke, Rankin 
et al. 2008). 
 
For patients with tumors who do not respond to imatinib, the approved second-line 
treatment is currently sunitinib. Here the median time to progression is 6.3 months 
compared to 1.4 months in untreated patients (Demetri, van Oosterom et al. 2006). 
Today there are several other TKIs with activity in advanced GIST that can be used as 
third-line treatment, including sorafenib, vatalanib, nilotinib and masatinib (Joensuu, 
De Braud et al. 2008; Montemurro, Schoffski et al. 2009; Le Cesne, Blay et al. 2010). 
There are also new TKIs undergoing trails, for instance pasopanib (SSG XXI, PAGIST, 
Scandinavian Sarcoma Group). 
 
Imatinib 
One could say that the imatinib story started in 1960 when Nowell and Hungerford 
reported their observation of a small abnormal chromosome in patients with chronic 
myeloid leukemia (CML)(Nowell and Hungerford 1960) (Figure 2). Ten years later the 
possibility of chromosome identification after banding was described by Caspersson 
and colleges. Using this technique Rowley et al. could show that this so-called 
Philadelphia chromosome resulted from of a translocation between chromosomes 9 and 
22 (Rowley 1973). The translocation was subsequently clarified on the molecular level 
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as generating the BCR-ABL fusiongene (Heisterkamp, Stam et al. 1985). The BCR-ABL 
oncogene which is detected in 95% of patients with CML, is the causative molecular 
abnormality in CML. In 1988 Yaish et al. reported he synthesis of tyrphostins (Yaish, 
Gazit et al. 1988), with specificity for individual tyrosine kinases. One of these 
tyrphostins was found to inhibit the bcr-abl kinase and could kill bcr-abl expressing 
cells in vitro (Kaur, Gazit et al. 1994). In parallel, Druker, Lydon and Bushdunger 
identified the kinase inhibitor CGP 57148 (now STI571, imatinib) that specifically 
inhibited the tyrosine kinase domain in abl, c-kit and PDGF-R. STI571 acts by blocking 
the ATP binding site of bcr-abl, and thus inhibit the phosphorylation of substrate 
needed for bcr-abl function (Buchdunger, Zimmermann et al. 1996; Druker, Tamura et 
al. 1996). All reviewed by Mauro et al. In the clinical trial published by Druker and 
collegues in 2001 imatinib was found to be well tolerated and remission was achieved 
in a large proportion of CML patients (Mauro and Druker 2001)  Imatinib was also 
found to be effective in GIST and the function in GIST is similar to CML. The c-kit 
receptor is normally activated by binding of the stem-cell factor ligand, followed by 
receptor autophosphorylation and triggering of cell-signaling cascades involved in 
apoptosis and proliferation. KIT mutations affecting the juxtamembrane domain are 
oncogenic leading to ligand-independent c-kit dimerization and activation of the kinase 
enzymatic domain. Imatinib treatment will block the ATP binding site of c-kit and 
inhibit enzyme activity leading to normalization of cellular functions(Miettinen and 
Lasota 2006; Corless, Barnett et al. 2011). 
 
 
Figure 2. Illustration of the BCR-ABL fusion (marked by circle) by fluorescent in situ 
hybridization and targeting of abl by imatinib.  
Imatinib   
 
 
 
BCR 
ABL 
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Adjuvant treatment  
There is evolving evidence to support adjuvant treatment, at least in “high-risk” 
patients. The Scandinavian Sarcoma Group (SSG XVIII) trial, which compared 12 and 
36 months of imatinib treatment in high risk GISTs, showed prolonged progression-
free survival and, somewhat unexpectedly, also prolonged overall survival for the 36 
month group (Joensuu, Eriksson et al. 2012). The ACOSOG Z9001 trial demonstrated 
significantly improved progression-free survival in patients who received one year of 
imatinib compared to placebo; however, the follow-up was short because the trial was 
discontinued prematurely when interim analysis showed significantly fewer recurrences 
in the treated group. In a study where patients with high-risk tumors were treated with 
adjuvant imatinib after radical surgery, the results were compared with historical 
controls; only one of 23 patients (4%) had a recurrence in the adjuvant treatment group 
compared to 32/48 (67%) in the control group (Nilsson, Sjolund et al. 2007). 
Estimation of the risk of recurrence after surgery for a GIST is of utmost importance 
when selecting patients who could possibly benefit from adjuvant treatment. 
 
Surgery is the standard treatment for patients with a primary resectable GIST, and the 
aim is to achieve complete resection with negative microscopic margins. Complete 
resection is possible in the majority of localized GISTs, but only about 60% remain 
recurrence-free for five years or more. Several risk stratification models have been 
proposed, such as the original NIH consensus criteria, to rank the risk of recurrent 
disease in resected GIST. However, the NIH criteria do not take into account tumor 
rupture, incomplete or intralesional surgical resection or tumor site. Joensuu et al. has 
proposed a modification of the NIH consensus criteria, to include tumor site and 
rupture as prognostic variables (Joensuu, Vehtari et al. 2012). 
 
In patients with tumors that are classified as “high risk”, surgical removal with 
microscopic free margins is followed by three years of adjuvant treatment with imatinib 
(standard treatment). An exception, depending on conferred resistance to imatinib, is 
patients whose GIST harbors the PDGFRA gene exon 18 substitution mutation D842V 
(Asp842Val) (Corless, Barnett et al. 2011) or NF-1 associated wtGIST (Mussi, 
Schildhaus et al. 2008); neither should be treated with adjuvant imatinib. Mutation 
analysis should always be carried out before adjuvant treatment, as an aid in treatment 
decisions (Joensuu 2012). 
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Neoadjuvant treatment  
Selected patients with primary inoperable tumors may benefit from the use of down-
staging treatment with pre-operative imatinib followed by surgery. Surgery for focal 
progressive lesions or metastasis (Maehara, Chijiiwa et al. 2008) could also be 
considered as part of the second- or third-line armamentarium in selected cases 
(DeMatteo, Maki et al. 2007; Zaydfudim, Okuno et al. 2012; Tielen, Verhoef et al. 
2013). Surgery of residual disease at best clinical response seems to be associated with 
survival benefit compared with historical controls in similar patient, treated with 
imatinib alone (Mussi, Ronellenfitsch et al. 2010; Doyon, Sideris et al. 2012; Roggin 
and Posner 2012). The suggested duration of treatment is within 6 months to avoid 
development of secondary mutations (Gold and Dematteo 2007). 
 
1.3 THE INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) 
The insulin-like growth factor (IGF) system is composed of three growth factors (IGF-
I, IGF-II and insulin), three membrane receptors (IGF-IR, IGF-IIR and insulin receptor 
(IR)), six circulating IGF binding proteins (IGFBP 1–6) and proteases that modulate 
ligand availability. IGFs are evolutionary conserved factors that regulate energy 
metabolism and growth. IGF-I acts through the type 1 IGF receptor (IGF-1R); signaling 
leads to downstream activation of pathways involved in proliferation, apoptosis, 
invasion/metastasis and angiogenesis (Figure 3). IGF signaling also influences hypoxia 
signaling, protease secretion, tumor cell motility and adhesion (Djiogue, Nwabo 
Kamdje et al. 2013; Walenkamp, Losekoot et al. 2013).  
 
Normally, IGF-I and IGF-1R are involved in 
pre- and postnatal growth; a deficiency leads to 
impaired pre- and postnatal growth, impaired 
brain development, sensorial hearing loss and 
failure to thrive (Walenkamp, Losekoot et al. 
2013; Wit and Walenkamp 2013).  
 
Figure 3. The IGF-1R signaling cascade. 
IGF-1R, a member of the insulin receptor family 
of the tyrosine kinase membrane receptor, is a 
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heterotetramer consisting of two ligand-binding extracellular α-subunits and two β-
subunits involving a transmembrane domain, an intracellular tyrosine kinase domain 
and a C-terminal domain. The subunits are linked together by disulphide bridges. 
Conformational changes occur when a ligand (IGFs or insulin) binds to the alpha 
subunits which enables autophosphorylation of the intrinsic tyrosine kinase domains 
subsequently initiating an intracellular signaling cascade. IGFs have 100-fold higher 
affinity than insulin to IGF-1R but insulin and IGFs can otherwise interact with each 
other’s receptors. The mediated effect is similar but the general opinion is that insulin 
mediates mainly metabolic responses, whereas IGFs and the IGF-1R mediate growth-
promoting effects (Pollak 2012; Varewijck and Janssen 2012). 
 
IGF-1R is frequently over-expressed in cancer and has been reported to be one of the 
major mediators of the growth and survival of cancer cells (Jernberg-Wiklund and 
Nilsson 2012), including sarcomas (Rikhof, de Jong et al. 2009). High expression of 
IGF-1R has been shown to be associated with poor prognosis and metastasis in a broad 
spectrum of cancer and sarcoma subtypes (Xie, Skytting et al. 1999; All-Ericsson, 
Girnita et al. 2002; Rikhof, de Jong et al. 2009; Asmane, Watkin et al. 2012; 
Mountzios, Kostopoulos et al. 2013).  
 
Recently, expression of IGF-1R was also detected in pediatric and wtGIST, where it 
seems to be linked to succinate dehydrogenase (SDH) deficient gastric GIST, whereas 
all small intestinal GISTs were negative (Lasota, Wang et al. 2013; Miettinen, Killian 
et al. 2013; Nannini, Astolfi et al. 2013). 
 
Insulin and IGFs are potent mitogens; their receptors have received considerable 
attention as therapeutic targets in oncology. Indeed, in sarcomas, activity has been 
observed clinically in e.g. Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, solitary 
fibrous tumor and synovial sarcoma (Sun, Gao et al. 2006; Hajdu, Singer et al. 2010) 
(Olmos, Martins et al. 2011), as well as in non-small-cell lung cancer, neuroendocrine 
tumors and prostate cancer. The encouraging early data on treatment of tumors via the 
IGF receptor family, have led to trials of drug candidates that target these receptors. 
However, the results of several recently reported trials have unfortunately been 
disappointing, mostly due to toxicity (the main side effects have been hyperglycemia, 
fatigue, and thrombocytopenia) but also because the benefit was limited to a small 
subset of patients, only 8-15% in Ewing sarcoma, and the duration of the response was 
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rather short in many patients due to the development of acquired resistance. 
Furthermore, biomarkers are not yet available to identify patients who could respond 
(Kim, Wan et al. 2009; Pollak 2012; O'Neill, Shah et al. 2013). 
 
1.4 EZRIN 
Ezrin is a member of the ezrin, radixin, moesin protein family (ERM) that has 
important functions in the organization and maintenance of the cell cortex, organization 
of the cytoskeleton, cellular morphology, migration and coordination of cell-to-cell 
signals (Crepaldi, Gautreau et al. 1997; Khanna, Khan et al. 2001; Ng and Streilein 
2001; Saotome, Curto et al. 2004). They also function as links between the extracellular 
environment, cell membrane and the underlying cytoskeleton and cytoplasm by 
interacting with the plasma membrane and the actin cytoskeleton. ERM proteins 
thereby regulate signaling pathways by linking transmembrane receptors to 
downstream signaling components, such as activation of T-cell and other lymphocytes. 
Ezrin has also been shown to be involved in the release of insulin granule in beta-cells 
(Arpin, Chirivino et al. 2011; Neisch and Fehon 2011). 
 
Khanna et al. (Khanna, Wan et al. 2004) and Yu et al. (Yu, Khan et al. 2004) initially 
reported that ezrin had high expression in highly metastatic osteosarcoma and 
rhabdomyosarcoma cell lines and that inhibition of ezrin significantly reduced the 
metastatic capability (Khanna, Khan et al. 2001; Hunter 2004; Khanna, Wan et al. 
2004; Park, Jung et al. 2006; Bulut, Hong et al. 2012). Over-expression of ezrin and 
subsequent uptake of the negative regulatory molecules might result in amplification of 
metastasis-associated signaling from the plasma membrane through the Rho-associated 
signal transduction pathways (Hunter 2004).  (Bretscher, Edwards et al. 2002; Hunter 
2004). 
 
Our findings, presented in Paper II, showed that ezrin expression in the primary tumor 
of initially metastasis-free STS patients was strongly associated with development of 
metastases during follow-up and consequently also with poor survival. The relationship 
between ezrin and tumor progression, metastasis and poor clinical outcome has also 
been shown in other tumors, including breast (Mak, Naba et al. 2012), uterus (Ohtani, 
Sakamoto et al. 2002), melanoma (Federici, Brambilla et al. 2009), and gastric (Jin, Jin 
et al. 2012). Similar findings have been reported for different types of STS in studies of 
malignant fibrous histiocytoma (Li, Akbari et al. 2008), STS (Carneiro, Bendahl et al. 
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2011) and GIST (Koon, Schneider-Stock et al. 2004), in which overexpression was 
significantly correlated with poorer disease-free survival (Wei, Li et al. 2009).  
 
Using ezrin as a target for cancer therapy is of great interest. Among others, Bulut et al. 
have reported the identification of two small molecules that interact directly with ezrin 
and inhibit its function in multiple assays, both in vitro and in vivo. Both molecules 
inhibited lung metastasis of ezrin-sensitive cells but not ezrin-resistant cells. These 
small molecule inhibitors are proposed as a novel targeted therapy that directly inhibits 
ezrin, as an approach to prevent tumor metastasis, and their development is suggested 
as novel anti-ezrin compounds for clinical use.(Bulut, Hong et al. 2012). 
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2 AIMS OF THE STUDY 
 
The purpose of this study was to identify molecular, pathophysiological and clinical 
characteristics associated with prognosis, in order to improve the management of 
patients with STS, including GIST, and ultimately affect the prognosis for the better. 
 
The natural course of highly malignant STSs cannot be predicted reliably at the time of 
diagnosis, and the question arises whether the patient should receive adjuvant therapy 
in addition to surgery. The aim of Paper I was to evaluate the prognostic impact of 
known and suggested prognostic markers, particularly IGF-1R, within a cohort of 
primary highly malignant STS. 
 
Ezrin is a cytoskeleton linker protein, involved in the growth and metastatic capacity of 
cancer cells. The aim of Paper II was to investigate the value of ezrin expression as a 
prognostic marker in clinical use, using immunohistochemical staining in primary 
highly malignant STSs. 
 
Imatinib is considered to be first-line therapy in patients with unresectable and/or 
metastatic GISTs and has dramatically changed the course of this disease, but side-
effects are common. The aim of Paper III was to evaluate the occurrence and 
prognostic significance of side-effects from imatinib treatment. 
 
Surgical resection with microscopically negative margin (R0) is widely considered to 
be a prerequisite for intended curative treatment of GIST. In STSs other than GIST, 
surgery is classified on the basis of resection margins into “intralesional”, equivalent to 
R1, and R0, which is subclassified into marginal and wide surgical margin, 
respectively. This classification has not been proven to be applicable to GIST. 
It has recently been reported that microGISTs mainly show an infiltrative growth 
pattern. To our knowledge this has not been investigated in other GISTs. The aim of 
Paper IV was to analyze the prognostic significance of resection margins defined as for 
other STSs, as well as to investigate the presence of infiltrative growth and pushing 
border and their correlation to surgical margins and prognosis in GISTs. 
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3 MATERIALS AND METHODS 
 
3.1 PATIENTS AND CLINICAL MATERIAL 
3.1.1 Highly malignant STS 
In Papers I and II, all highly malignant STS patients primarily operated at the 
Orthopedic Department, Karolinska University Hospital, during the period 1985 to 
1993 were included. Only patients treated for highly malignant STS (grade 3 or 4), 
without metastases at the time of diagnosis, who had not received any preoperative or 
postoperative adjuvant treatment, were selected. All patients were operated with a 
curative intent. An experienced histopathologist, without knowledge of the clinical 
course or the primary histology, re-evaluated all cases (in total 128 patients). After 
exclusion of patients with Ewing sarcoma, osteosarcoma, low malignancy grade or 
non-STS, 101 cases remained for evaluation.  
 
In Paper I, all 101 patients were included. There were 47 males (47%) and 54 
females (53%); the mean age at diagnosis was 62 years (range 5-90 years). The 
primary tumors were located in either the lower extremities (n = 66), the upper 
extremities (n = 16), the pelvic area (n = 9), the trunk or the abdominal wall (n = 10). 
The histopathological entities included malignant fibrous histiocytoma (n = 65), 
liposarcoma (n = 16), malignant peripheral nerve sheath tumor (n = 4), synovial 
sarcoma (n = 3), fibrosarcoma (n = 3), alveolar STS (n = 3), leiomyosarcoma (n = 2), 
mesenchymoma (n = 1), rhabdomyosarcoma (n = 1), spindle cell sarcoma (n = 1), 
angiosarcoma (n = 1), and high-grade sarcoma NOS (n = 1). 
 
A subset of the cases from Paper I were included in Paper II. They comprised 24 
men (48%) and 26 females (52%) with a mean age of 60 years at diagnosis (range 19-
81years). The primary tumors were localized in the lower extremities (n = 33), the 
upper extremities (n = 6), the pelvic area (n = 6), or the trunk or abdominal wall (n = 
5). The different histopathological entities included malignant fibrous histiocytoma (n 
= 34), liposarcoma (n = 7), malignant peripheral nerve sheath tumor (n = 2), synovial 
sarcoma (n = 1), fibrosarcoma (n = 1), alveolar STS (n = 2), mesenchymoma (n = 1), 
angiosarcoma (n = 1), and high-grade sarcoma NOS (n = 1). 
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3.1.2 GIST 
In Paper III, 75 patients diagnosed with GIST who had received imatinib treatment at 
the Karolinska University Hospital, Sweden, were included. Patient records were 
reviewed retrospectively. All patients had been treated with surgery and imatinib 
between 2002 and 2010. The size of the tumor ranged from 2.5 to 28 cm. Totally 37 
tumors were >10 cm, 24 were 5-10 cm, 9 were <5 cm, while in one case the size was 
not available. All but 6 patients were classified as high risk. 
 
The indication for imatinib treatment was metastatic or recurrent disease, diagnosed 
before initiation of imatinib therapy in 31 cases; another 3 cases were defined as 
having metastatic disease as a consequence of earlier invasive procedures 
(exploratory laparotomy with open biopsy or external drainage). These patients 
received imatinib as neoadjuvant (n = 10), palliative (n = 12), recurrence (n = 10) or 
adjuvant (n = 2) treatment. The remaining 41 patients received imatinib treatment as 
adjuvant treatment (n = 31) or neoadjuvant treatment (n = 10). 
 
In Paper IV, a cohort of 83 patients diagnosed with GIST, admitted to Karolinska 
University Hospital 1997-2010 and with available data on surgical margins, was 
analyzed. The cohort was selected from an initial cohort of 129 patients after exclusion 
of patients who had received neo or adjuvant treatment with imatinib (n = 31) or had 
metastasis at diagnosis (n = 15). The 83 patients comprised 46 females (55%) and 37 
males (45%). Most of the tumors were located in the ventricle (n = 46), followed by 
small intestine (n = 24), duodenum (n = 5), colon (n = 3), rectum (n = 3) and esophagus 
(n = 2). Thirty-two were classified as high risk, 17 as intermediate risk and 34 as low or 
very low risk tumors according to NIH risk criteria. No micro GIST, defined as tumor 
smaller than 1 cm, was included. There were 19 tumors with a largest diameter >10 cm, 
20 with >5-≤10 cm, 35 with 2-5 cm and 6 with <2 cm.  
 
For 67 of the 83 patients (36 females (54%) and 31 males (46%)), hematoxylin slides 
were available with evaluable tumor border for analysis of growth pattern. Thirty-two 
of these tumors were localized in the ventricle, 7 in duodenum, 20 in the small 
intestine, 4 in rectum, 2 in colon and 2 in esophagus. Thirty-one were classified as high 
risk, 12 as intermediate risk and 24 as low or very low risk tumors. 
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3.2 CLINICAL ASESSMENTS 
 
3.2.1 Follow-up in in STS and GIST 
In Papers I and II, including highly malignant STSs, the patients were followed at the 
Orthopedic Department, Karolinska University Hospital, until either October 2001 or 
the patients’ death, and the occurrence of metastasis and/or local recurrence was 
recorded. The patients were divided into the following groups depending on the type 
of recurrent disease: 
1.  Patients who had no evidence of disease during follow-up (DFS). This group was 
used as a reference in calculations of local recurrence and metastasis. 
2. Patients who developed local recurrence but no metastases during follow-up (Only 
Lrec). 
3. Patients with metastases but no local recurrence during follow-up (Only Met). 
4. Patients who had developed both local recurrence and metastases during follow-up 
(Lrec + Met). For this group, the date of the first event was used in the statistical 
analyses.  
5. Separate calculations were also done for the group of patients who developed local 
recurrence irrespective of metastases during follow-up (All Lrec) and the patients 
with metastases irrespective of local recurrence during follow-up (All Met).  
6. All patients who were alive, without evidence of disease at the end of follow-up 
(NED), were used as reference in calculations of death from or with disease, 
irrespective of whether they had either local recurrence or metastasis during 
follow-up.  
 
In Paper II, time to metastasis and local recurrence were used in the analyses. For 
patients with both local recurrence and metastasis, time to metastasis was used in the 
calculations. As in Paper I, all patients who were alive without evidence of disease at 
the end of follow-up, regardless of whether they had recurrence or metastasis during 
follow-up, were used as reference in the calculations of survival concerning death 
from or with disease. 
 
In Paper III, all patients were followed-up routinely for tumor recurrence. Tumor 
response was evaluated by FDG-PET (11 cases in the neoadjuvant group) and/or 
contrast-enhanced CT (n = 75) and histopathological examination of the excised tumor 
(n = 75). Follow-up was defined as time from initiation of imatinib treatment to last 
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documentation of state, i.e. no evidence of disease (NED), evidence of disease (ED) or 
death. 
 
In Paper IV, all patients were followed-up routinely for recurrent or metastatic disease 
with contrast-enhanced CT every 6 months or in the event of symptoms. The patients 
were followed-up until death or March 2012. Recurrence, site of recurrence, metastasis 
and cause of death were registered. The 83 patients included in analyses for surgical 
margins had a median follow-up of 61 months (range 8-154 months) and the 67 
patients included in the analyses of growth pattern had a median follow-up of 61 
months (range 8-154 months) 
 
3.2.2 Tumor size 
In all Papers, tumor size was defined as the largest diameter, assessed by examination 
of the resected specimen; the figures were taken from the histopathological report. 
 
In Paper I, the patients were divided into three groups according to size: ≤6 cm, 7-11 
cm and >10 cm. 
 
In Paper II, the median size was 11 cm (range 1-23 cm) and the actual diameter was 
used in the calculations.  
 
In Paper III, the observed tumor size ranged from 2.5 cm to 28 cm and was subgrouped 
as <5 cm, 5-10 cm, or >10 cm.  
 
In Paper IV, the median diameter was 6.8 (range 1.2 -28 cm); in the calculations, all 
cases were subgrouped as <2 cm, 2-5 cm, >5-≤10 cm or >10 cm. 
 
3.2.3 Imatinib side effects in GIST 
In Paper III, records from all patients were carefully reviewed for side-effects and the 
history of moderate to severe or life-threatening side-effects was classified according to 
Common Terminology Criteria for Adverse Events v4.0 (CTCAE).  
 
3.2.4 Surgical margin 
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The definition of surgical margin used in this thesis comes from the Centralized 
Registration of Sarcoma Patients in Scandinavia (SSG VII http://www.ssg-
org.net/treatment-protocols-and-recommendations/ongoing). The definition is modified 
from Enneking et al. (Enneking, Spanier et al. 2003). 
 
Surgical margins in STS  
In Paper I surgical margins were assessed at surgery and upon pathological 
macroscopic and microscopic examination. The tissue coverage of the specimen with 
the poorest margin was recorded. 
 
Cases with positive margin included:  
Gross tumor left: When macroscopic tumor tissue is left behind, as reported by the 
surgeon. This is equivalent to R2 resection. 
Intralesional: When microscopic tumor is reported at the resection border,as  judged 
by the pathologist. This also includes situations when leakage of fluid/tissue occurs 
during surgery from the tumor into the wound, as when the tumor is ruptured or the 
pseudocapsula is injured. This is equivalent to R1 resection. 
 
A negative microscopic margin is equivalent to R0 resection. The classification is 
based on the shortest distance (mm) between the tumor and resection border in an area 
where there is no fascia between the tumor and resection border. The distinction 
between a marginal and a wide margin is made by the surgeon, based on the combined 
information from surgery and histopathological examination. 
 Two types of negative margin are defined:  
Marginal margin: There is microscopically negative margin but with a close margin in 
at least one portion of the tumor, regardless of how much healthy tissue there is 
elsewhere around the tumor.  
Wide margin: There is either a cuff of healthy tissue of at least 20 mm that must be 
present all round the tumor, or an unengaged fascia. An intact fascia is considered 
sufficient for wide margin, irrespective of the distance between tumor and fascia. 
 
Surgical margin in GIST 
In Paper IV, surgical margins were assessed during surgery, complemented by 
subsequent histopathological examination. The definition used is the same as for 
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surgical margins of STS in other locations, modified to be applicable to STS in the 
abdominal cavity, including GIST, and the retroperitoneal space. 
 
Intralesional margin: Defined as R1 resection (microscopically positive margins), 
which includes tumor enucleation or when the surrounding peritoneal surface is 
damaged.  
Marginal margin: Defined as R0 resection (microscopically negative margins, i.e. 
tumor-free (Wittekind, Compton et al. 2002)), with less than 2 cm in the organ of origin 
or in tissue adherent to the tumor. 
Wide margin: Defined as R0 resection with >2 cm surgical margin in the organ of 
origin with a completely intact peritoneal surface covering the tumor and “un-bloc” 
resection of surrounding organs and structures that are adherent to the tumor. 
 
3.2.5 Peripheral growth pattern in GIST 
The peripheral tumor growth pattern was classified as pushing border or infiltrative 
growth.  The definitions applied are in accordance with the classification applied by 
Engellau et al. for soft tissue sarcomas (Engellau, Bendahl et al. 2005; Rossi, 
Gasparotto et al. 2010; Wu, Hou et al. 2011). 
 
Pushing border: The tumor border was free from growth of tumor cells outside the 
tumor restriction in the surrounding normal tissue. 
Infiltrative growth: There were findings of tumor growth outside the tumor pseudo-
capsule or tumor cells infiltrating the surrounding normal tissue outside the tumor 
restrictions. 
 
3.3 EXPERIMENTAL METHODS 
 
3.3.1 Immunohistochemistry 
Immunohistochemistry was used to evaluate protein expression and localization in 
Paper I and II. Paraffin-embedded tissue from the primary tumor was available for all 
cases; the single most representative tumor tissue block was used for 
immunohistochemical analyses. 
 
Paraffin sections of 4 µm were deparaffinized, rehydrated, and pretreated with citrate 
buffer at pH 6 in a microwave for 20 minutes. After rinsing, the endogenous peroxidase 
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activity was blocked by treatment with 0.5% hydrogen peroxide for 30 minutes. The 
sections were then rinsed and incubated with blocking serum for 20 minutes. 
 
The primary antibody was applied and sections were incubated overnight in a moist 
chamber at +8 °C (Ezrin, +4 °C). A biotinylated anti-mouse immunoglobulin G, used 
as secondary antibody, was incubated for 30 minutes, followed by rinsing in the 
avidin-biotin complex for another 30 minutes. The peroxidase reaction was developed 
using 3,3-diaminobenzidine for 6 minutes and nuclear counterstaining. TBS (pH 7.4) 
was used for rinsing between the steps.  
 
In Paper I, the following antibodies were used for antigen detection: anti human-Bcl-2 
oncoprotein, DO-1 for p53, Mib-1 for Ki-67, Clone F8/86 for anti-human von 
Willebrand Factor, Kip-1 for p27, and a polyclonal antibody to the IGF-1R a-subunit 
(N20 Santa Cruz Biotechnology). In control experiments, slides from 10 of the cases 
were incubated with another polyclonal antibody against the IGF-1R h-subunit (H60 
Santa Cruz). The immunohistochemical staining was done according to the standard 
ABC technique. For IGF-1R, the same method for immunostaining was done as for the 
other antibodies, except that the 20-minute pretreatment with citrate buffer was omitted 
and biotinylated anti rabbit immunoglobulin G was used as a secondary antibody. 
Paraffin sections from tissues known to be negative or positive for the respective 
markers were analyzed in parallel as negative and positive controls.  
 
In Paper II, a primary mouse monoclonal antibody against ezrin was applied. Paraffin 
sections from placenta collected after birth and normal mesenchymal tissues from 
liposarcoma patients were analyzed in parallel as positive and negative controls, 
respectively.  
 
Scoring of immunohistochemical slides 
In Paper I, for Bcl-2, p53, Ki-67, and p27, the degree of staining was calculated as the 
proportion of positive cells using a 10 x 10 grid in 10 HPFs (200 x). For each HPF, the 
total numbers of positive and negative cells were determined by counting all positively 
stained cells in two or more representative rows and multiplying to 10 x 10. The 
scoring was done by one independent observer for all cases and by two independent 
observers for randomly selected cases. In the evaluation of vessel density, 10 fields 
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(200x) with the most intensive neovascularization (hotspot) were evaluated, and all 
vessels stained by Factor VIII were counted.  
 
The IGF-1R staining was evaluated by three independent observers using a 
semiquantitative approach by which the proportion of positive cells was scored in 25% 
intervals, giving either negative tumors (0% positive cells) or positive tumors (1-25%, 
26-50%, 51-75%, or 76-100% positive cells). In addition, the STSs with positive IGF-
1R expression were also evaluated for relative staining intensity on the cellular level.  
 
In Paper II, the immunostaining for ezrin was scored for all cases by two observers in 
an open discussion without knowledge of the clinical details. First, the ezrin expression 
was scored as positive or negative. Negative cases included those where no tumor cells 
showed cytoplasmic immunoreactivity or where only single tumor cells showed 
immunoreactivity. All cases scored as positive showed ezrin immunoreactivity in the 
cytoplasm of a subset or all tumor cells. Positive cases were also evaluated concerning 
the proportion of positively stained cells. A semiquantitative approach was used 
whereby the tumors were grouped into four classes with 1% to 25%, 26% to 50%, 51% 
to 75%, or 76% to 100% positively stained cells. For these quantitative analyses, 
positive cells were only counted in areas with a high proportion of tumor cell 
representation, whereas areas with necrosis and/or lymphocyte infiltration were 
excluded to rule out an incorrectly high proportion of positively stained cells.  
 
3.4 STATISTICAL METHODS 
 
Correlations between clinical, immunohistochemical and histopathologic variables and 
outcome during follow-up were analyzed. Recurrence-free survival was measured from 
date of diagnosis (start of imatinib treatment in Paper III) to the time of first 
recurrence, most recent follow-up or death. The results were calculated using the log-
rank test and illustrated by Kaplan-Meier plotting. Prognostic factors were compared  
using Cox proportional hazards model; correlation analyses were done with Spearman 
rank order test. The calculations were done with Statistica 6.0 software for Papers I and 
II, Statistica 10.0 software for Paper IV, and the PASW for Windows statistical 
package 18.0 for Paper III.  P <0.05 was considered to be statistically significant. 
 
   35 
In Paper I, each variable was evaluated in a series of cut-off values. The cut-off that 
gave the best P-value is presented in the tables and used in the statistical analyses.  
 
In Paper II, associations between ezrin expression and recurrent disease, irrespective of 
time, were calculated by Chi-square test in addition to other analyses. 
 
In Paper III, Pearson’s Chi-square test was used to compare the distribution of patient 
and tumor characteristics between groups.  
 
In Paper IV, time from diagnosis to recurrence, metastasis and tumor free survival were 
compered to outcome in the different groups by calculating with Kaplan-Meier lot, Chi-
square test as well as cox regression analysis and correlation analysis. 
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4 RESULTS AND DISCUSSION 
 
4.1 IGF-1R EXPRESSION IN HIGHLY MALIGNANT STS (PAPER I) 
 
The purpose of this study was to evaluate known and suggested prognostic markers, in 
particular the insulin growth factor type 1 receptor (IGF1R), in highly malignant soft 
tissue sarcoma (STS). In this patient group which is known to entail a high risk of 
recurrence, it can be difficult to identify which patients will develop a recurrence or 
metastases and thus, could be considered for additional adjuvant treatment. 
 
The study includes 101 patients with orthopedic STSs of high malignancy grade that were 
evaluated with respect to previously known prognostic factors such as gender, location 
(deep / subcutaneously), tumor size, necrosis, vascular ingrowth, infiltrative growth 
pattern, mitotic index, surgical margin and grade 3 or 4. We also determined 
immunohistochemical expression of cell cycle factors (p53 and p27), apoptosis marker 
(Bcl-2), MIB-1 proliferation index (Ki-67), and a growth factor (IGF-1R). 
Neovascularization was assessed as vessel density  by Factor VIII labeling of the 
endothelium. Sections from paraffin-embedded material were incubated with the current 
antibody and the proportion of positive cells was counted in a grid (10x10 lines). In the 
assessment of vascular density, the number of vessels was counted in the same grid 
pattern.  
 
Tumor size was found to be the most prominent prognostic factor among which 11 cm and 
6 cm, were most significant. Thus, patients with tumors smaller than 6 cm had a good 
prognosis, while those with tumors larger than 11 cm had a generally poor prognosis. 
Other clinical and histopathological parameters with prognostic significance were deep vs. 
subcutaneous localization, necrosis, mitotic rate and to some degree surgical margin. 
Although necrosis and mitotic index are included as part of the malignancy grading, no 
difference in prognosis was found between malignancy grades 3 and 4. These data suggest 
that a two-grade (low malignant/high malignant) or three-grade scale may be sufficient for 
an adequate assessment of malignancy grade and risk of recurrence. Moreover, the 
individual components necrosis and mitotic index are more relevant than the overall 
assessment.  
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No prognostic value could be demonstrated for the parameters gender, infiltrative growth 
pattern and vascular invasion. Infiltrative growth pattern was seen in 93% of the cases, 
indicating that this characteristic is common in highly malignant STS but lacks prognostic 
significance in this group of highly malignant tumors. 
 
Among the immunohistochemical markers, only IGF-1R expression and vascular density 
were significantly associated with prognosis. Vascular density showed correlation to death 
from or with disease as well as to survival. However, results in other studies are divergent 
and further studies are needed to determine the prognostic importance of vascular density 
in STS. 
 
Insulin-like growth factors (IGFs) are normally involved in the intrauterine and postnatal 
growth and development of tissues and organs. IGF-1 receptor (IGF-1R) is a cell 
membrane receptor activated by its ligands IGF-1 and IGF-2. Activation effects on 
proliferation, differentiation and apoptosis, as well as deficiency, lead to impaired pre- and 
postnatal growth, impaired brain development, sensorial hearing loss and failure to thrive. 
We have found that IGF-1R is expressed in approximately half of the tumors, which 
indicates that this system is frequently activated in STS. Furthermore, our study has shown 
that high expression of IGF-1R is associated with a reduced risk of death in or with 
disease, as well as with improved overall survival, compared with tumors showing a low 
number of IGF-1R-positive cells. Therefore, IGF-1R may be a factor of potential 
prognostic significance. 
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4.2 PROGNOSTIC VALUE OF EZRIN EXPRESSION IN HIGHLY 
MALIGNANT STS (PAPER II) 
 
Earlier findings in other sarcomas, such as osteosarcoma and rhabdomyosarcoma, 
indicated that ezrin were of interest and might be a key component in tumor 
progression and metastasis. In the study of Khanna et al. the role of ezrin expression in 
development of metastasis was demonstrated in a mouse model, in a natural dog model 
as well as in pediatric osteosarcoma patients (Khanna, Wan et al. 2004). The aim of 
Paper II was to investigate ezrin, using immunohistochemical expression, as a 
prognostic marker for clinical use in highly malignant STS.  
 
The study includes 50 cases with primary STS of malignancy grade 3 or 4, which were 
also part of Paper I. None of the patients had local or distant metastases at the time of 
the initial surgery, and none had received pre-or post-operative adjuvant treatment.  
Follow-up was done retrospectively for at least 4 years or until death. Information 
about survival, metastasis and local recurrence were collected and analysed separately 
against ezrin expression.  The results show that 26 of the 50 patients developed 
metastasis (52%), 16 patients developed local recurrence (32%) and 16 remained 
without any recurrent disease (32%); thus, 8 patients had both metastasis and local 
recurrence. Of the 34 patients who developed recurrent disease, 28 (82%) died and the 
other 6 (18%) were alive without any sign of disease at the end of the follow-up.  
 
The expression of ezrin was determined by immunohistochemistry using a monoclonal 
antibody. Placenta was used as a positive control and normal mesenchymal tissue from 
a liposarcoma patient served as negative control. The results were evaluated concerning 
positive/negative cases as well as concerning the proportion of ezrin expressing cells in 
positive cases. Half of the cases were found positive showing immunoreactivity in the 
membrane and cytoplasm in 1 to 100% of the tumor cells, as exemplified in Figure 4. 
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Figure 4. Photomicrograph showing immunohistochemical expression of ezrin in a 
highly malignant STS. 
 
Positive ezrin expression was associated with development of metastasis and with short 
survival (Figure 5). Of the 25 positive cases, 17 developed metastasis, compared with 
only 9 of the 25 negative cases (P = 0.023). Distant metastases were significantly more 
frequently in patients with ezrin-positive as compared to ezrin-negative tumors (P = 
0.031). No association was found between ezrin expression and local recurrence. Ezrin 
expression was also shown to be an independent prognostic marker for development of 
metastatic disease in multivariate analyses and consequently also associated with death 
from disease (P = 0.014) as well as with overall survival (P = 0.007).  
 
Interestingly, a comparison of results from Paper I showed that ezrin expression was 
significantly correlated to infiltrative growth pattern (P = 0.03). None of the other 
tested parameters was significantly correlated to ezrin. Tested parameters were: clinical 
(sex, size, site, and depth), histopathological (malignancy grade, necrosis, and mitoses), 
and immunohistochemical expression of Ki-67, p53, p27, Bcl-2, IGF-IR, or Factor VIII 
(i.e. antigens involved in proliferation, differentiation, angiogenesis, and apoptotic 
processes). Furthermore, in a subset of cases previously analyzed for DNA copy 
number alterations using comparative genomic hybridization, a strong correlation was 
found between ezrin expression and copy number gain of chromosomal region 9cen-
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q22 (R = 0.47, P = 0.02). However no association was observed between ezrin 
expression and alterations of the region harboring the ezrin coding gene in the long arm 
of chromosome 6.  
 
 
 
 
Figure 5. Kaplan-Meier plots showing associations between positive ezrin expression 
and development of metastases (top) and shorter overall survival (bottom).  
 
In conclusion, our findings show that high ezrin expression in the primary tumor of 
initially metastasis-free STS patients is strongly associated with development of 
metastases during follow-up and consequently also with poor survival. A relationship 
between ezrin and tumor progression, metastasis and poor clinical outcome has also 
been shown in other tumors, including various types of STS, malignant fibrous 
histiocytoma (MFH) (Li, Akbari et al. 2008), STS generally (Carneiro, Bendahl et al. 
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2011) and GIST (Koon, Schneider-Stock et al. 2004), where over-expression 
significantly correlated with poorer disease-free survival (Wei, Li et al. 2009). 
 
4.3 SIDE-EFFECTS AND OUTCOME IN IMATINIB TREATED GIST 
(PAPER III) 
 
GIST is commonly treated by surgery alone or in combination with a TKI such as 
imatinib. The standard treatment is surgery with negative tumor margins (Casali, Jost et 
al. 2008; Joensuu, Vehtari et al. 2012). However, only about 50% of the tumors  are 
localized at the time of diagnosis (Nilsson, Bumming et al. 2005; Tryggvason, Gislason 
et al. 2005). Therefore curative surgery is often not possible and many patients relapse 
(DeMatteo, Lewis et al. 2000). While GISTs are resistant to conventional chemo- and 
radiation therapy (Joensuu, Roberts et al. 2001) the use of TKIs have proven highly 
successful.  Indeed, the c-kit tyrosine kinase inhibitor imatinib has significantly 
improved the outcome of advanced GIST. Imatinib mesylate is now considered the 
standard first-line treatment for advanced and recurrent GIST and also for adjuvant 
treatment (Demetri, von Mehren et al. 2002; Dematteo, Ballman et al. 2009). 
Neoadjuvant treatment in primarily unresectable GISTs may permit complete resection 
(R0) and also organ-saving surgery (Eisenberg, Harris et al. 2009; McAuliffe, Hunt et 
al. 2009). Adjuvant treatment offers improvement in progression-free survival 
(Dematteo, Ballman et al. 2009; Joensuu, Eriksson et al. 2012). 
 
The medication is relatively well tolerated, but side effects are encountered in almost 
all patients (Joensuu, Trent et al. 2011), which may be more severe for higher doses 
(Blanke, Rankin et al. 2008; Dematteo, Ballman et al. 2009). However, the relationship 
between side effects and imatinib plasma concentrations is not clear (Cortes, Egorin et 
al. 2009) (Yoo, Ryu et al. 2010). Interestingly, low plasma concentrations of imatinib 
have been associated with a shortened time to disease progression (Demetri, Wang et 
al. 2009). Given these circumstances we here aimed to monitor the development of 
imatinib side-effects and their possible influence on patient outcome in GIST patients 
treated at our institution. For this purpose, a cohort of patients was identified and 
retrospectively reviewed concerning tumor characteristics, treatment, side effects and 
follow-up. 
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The study includes 75 GIST patients who had been operated and treated with imatinib. 
The tumor size ranged from 2.5 to 28 cm and cases were sub-grouped as <5 cm, 5-10 
cm, or >10 cm. The tumors were located in esophagus (n = 2), stomach (n = 34), 
duodenum (n = 7), small intestine (n = 24), colorectal (n = 7) or uncertain (n = 1). The 
risk of recurrence was defined using the modified consensus classification of NIH, 
based on primary tumor size, location, rupture and mitotic index (Joensuu 2008). The 
classification criteria gave 69 patients at high risk and 6 patients at intermediate risk. 
The median follow-up time from the initiation of imatinib treatment until the last 
examination or death was 48 months (4–107 months).  
 
Totally 41 patients without known metastatic disease at diagnosis had received 
neoadjuvant or adjuvant treatment with imatinib due to high risk, intermediate risk or 
primarily inoperable tumor. Metastatic or recurrent disease was diagnosed in 31 
patients and an additional 3 patients were treated as if they had metastasis due to 
ruptured disease. These patients received imatinib in a neoadjuvant, palliative, or 
adjuvant setting.  
 
The side-effects were classified according to the Common Terminology Criteria for 
Adverse Events v4.0 (CTCAE) as grade 1 (mild), grade 2 (moderate), grade 3 (severe), 
grade 4 (life-threatening) or grade 5 (death related to adverse effects).  
Grade 2-4 side-effects were observed in 30 patients. Life-threatening complications 
occurred in two cases in the form of agranulocytosis and tumor rupture, respectively. 
The other 28 patients showed dermatitis/rash (n=15), gastrointestinal symptoms (n = 9), 
edema (n = 7), muscle cramps (n = 4),fatigue (n = 2) and several other side effects in 
single cases. 
 
Overall, the side-effects occurred already after a short period of treatment. In 9 cases 
this lead to interruption of the treatment because of symptoms such as agranulocytosis 
(n=1), dermatitis, rash (n = 6), pruritus (n = 2), edema (n = 2), nausea, diarrhea (n = 3), 
and myalgia and muscle cramps (n = 1).  
 
Among patients with metastatic or recurrent disease a significant association between 
presence of side-effects and favorable recurrence-free survival was observed (P = 0.01) 
(Figure 6).  However, side effects were not associated with other clinical parameters. 
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Figure 6. Kaplan-Meier plot showing better recurrence-free survival in patients with 
metastatic/recurrent GIST and side-effects from imatinib treatment.  
 
The observation of improved survival for GIST patients with imatinib side-effects is of 
interest and raises several questions about the underlying mechanism and possible 
implications. First, it is possible that side effects from imatinib treatment reflect higher 
concentrations of the drug and unwanted effects on e.g. the abl target. This could be 
related to several factors such as drug uptake, metabolism, and tumor cell uptake. A 
natural continuation of this study would be comparison of side-effects with plasma 
concentration of imatinib. However, such analyses are not used routinely in clinical 
practice, while such information is not available for the present series. Prospective 
analysis of imatinib concentrations in comparison to side-effects and outcome are 
encouraged based on the present data. Furthermore, the occurrence of adverse effects 
may reduce patient compliance and discontinuation of imatinib treatment has been 
reported to result in rapid tumor progression in patients with advanced GIST (Le Cesne, 
Ray-Coquard et al. 2010). Based on the results in Paper III the first clinical translation 
is suggested to be further support of patients to continue imatinib treatment without any 
interruptions also in the presence of tolerable side-effects.    
 44 
 
4.4 SURGICAL MARGIN, GROWTH PATTERN AND OUTCOME IN GIST 
(PAPER IV) 
GIST patients are presently treated by surgery and / or a TKI which has dramatically 
improved results during the last decade. While the surgical intervention is the only 
possible curative option, TKI virtually requires life-long treatment which is associated 
with development of drug resistance at some point of the treatment. Therefore further 
development of the surgical intervention to achieve curative or delay recurrence is 
desired. . In operable patients treated with surgery alone, the estimated 15-year 
recurrence-free survival rate is presently approximately 60% (Joensuu, Vehtari et al. 
2012). An example of the surgical intervention is shown in Figure 7. 
 
 
 
 
Figure 7. Photograph showing an GIST in the stomach during surgery.  
 
A resection with microscopically negative margin (R0) is a prerequisite to achieve 
curative treatment in GIST (Catena, Di Battista et al. 2012). This notion is partly 
supported by reports showing that tumor rupture is associated with a worse prognosis 
(Rutkowski, Nowecki et al. 2007; Joensuu, Vehtari et al. 2012). In STS other than 
GIST, surgery is classified on the basis of resection margins into intralesional 
(equivalent to R1 resection), marginal (equivalent to R0 resection but with < 2 cm 
normal tissue in the organ of origin and/or intact fascia), or wide( also R0 but with >2 
cm margin and/or intact fascia), modified from Enneking et al.(Enneking, Spanier et al. 
2003). This has been shown to have prognostic significance in STS (Trovik, Bauer et 
al. 2000; Sampo, Tarkkanen et al. 2008), however the classification has not yet been 
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proven to be applicable to GIST. The aim of this study was therefore to analyze the 
prognostic significance of surgical resection margins in surgery for GISTs.  
In addition we aimed to examine the peripheral growth pattern and its relation to patient 
outcome and surgical margins. Micro-GISTs (less than 1 cm) have recently been 
reported to show a mainly infiltrative growth pattern (Rossi, Gasparotto et al. 2010); to 
our knowledge this has not been investigated in large GIST. 
 
The GIST cohort studied was identified from all patients admitted to our institution. In 
the entire cohort, established prognostic criteria were associated with time to first event 
(local/peritoneal or metastatic recurrence) as expected including:  size (P = 0.003), 
mitotic index (P = 0.00006) and tumor site, calculated as gastric or non-gastric (P = 
0.003).  
 
Surgical margin 
A total of 83 patients without metastasis at diagnosis who had not received any 
neoadjuvant or adjuvant treatment were included in the study of surgical margin, 37 
males and 46 females (Table 5). Tumor size was based on the largest diameter and 
subgrouped as <2 cm (n = 6), 2-5 cm (n = 35), >5-10 cm (n = 20) or >10 cm (n = 19). 
Mitotic index was defined as the number of mitoses in 50 HPF and subgrouped as low 
(<2, n = 39), intermediate (2-10, n = 23) or high (>10, n = 12). Recurrence was defined 
as local/peritoneal if it was at the site of origin or in the peritoneum. Metastatic disease 
was defined as recurrence at a distant location, most commonly the liver. Risk 
stratification was classified as High (n =32), Intermediate (n = 17) or Low or very low 
(n = 34). The median follow-up time for patients with non-recurrent disease was 61 
months. Thirty of the patients developed recurrent disease, distributed as 
local/peritoneal recurrence in 22 cases and metastasis in 16. Eleven patients died from 
disease during follow-up. The median time to any event was 41 months (range 2-274 
months). 
 
A wide surgical margin was observed in 40 cases, 24 cases had marginal margin and 19 
case intralesional margin. Local/peritoneal recurrence was diagnosed in 2/40 cases with 
wide margins, in 7/24 cases with marginal margins, and in 13/19 cases with 
intralesional surgery. The risk was thereby significantly higher for patients with 
marginal [hazard ratio HR 6.3 (1.3-30.4)] and intralesional [HR 11.3 (2.5-51)] margins 
as compared to wide surgical margins (P = 0.002) (Figure 8). Surgical margin remained 
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a significant independent risk factor for local/peritoneal recurrence after adjustment for 
tumor size and site; (marginal HR 6.5 (1.3-31.9) and HR 6.2 (1.3-30.1); intralesional 
HR 9.8 (2-48.2) and  HR 9.6 (2.1-44.7)). No differences in outcome were observed 
between patients operated with marginal compared with intralesional margins. Wide 
surgical margin was significantly associated with prolonged time to distant metastases 
(P = 0.005) and inversely correlated to death from disease (P = 0.02). 
 
 
Figure 8. Kaplan-Meier plots showing longer time to recurrence in GIST patients 
operated with wide surgical margin. 
 
In summary, a wide surgical margin was strongly associated with a reduced risk of 
local recurrence or metastasis and with longer tumor-specific survival, compared with 
narrow or intralesional surgical margins. The results show that precautions must be 
taken to obtain true free microscopic margins. 
 
Peripheral tumor growth pattern 
A total of 67 patients, 31 males and 36 females, were included in the analysis of growth 
pattern. Median age at diagnosis was 61 years (range 10-86 years) and median follow-
up was 61 months (range 8-154 months). The correlation analysis between surgical 
margins and peripheral growth pattern included only the 56 patients who were without 
metastasis at diagnosis. 
 
   47 
An infiltrative growth pattern was observed in more than half of the GISTs, 43 out of 
67 (64%), while 24 cases (36%) had a pushing border (Figure 9); which is almost 
similar to findings in micro-GISTs (63%).  
Inﬁltra(ve+growth+ Pushing+border+A+
B+
C+
D+
E+
F+
Figure 1. A-C Infiltrative growth, D-F Pushing border 
 
Figure 9. Hematoxylin slides of GISTs with infiltrative growth (left) or pushing border 
(right). 
 
 
 48 
 
An infiltrative growth pattern was significantly associated with a shorter time to first 
event, compared to pushing border (P = 0.027 (Figure 10). However, when analyzed 
separately, infiltrative growth was not associated with local/peritoneal recurrence, 
metastatic disease or survival. Contrary to our expectations, no correlation was 
observed between growth pattern, surgical margin and outcome. This was the case even 
when patients resected with marginal margins were analyzed separately; in view of the 
narrow surgical margin, one might expect that tumors with infiltrative growth would 
recur more often within this group. 
 
 
 
Figure 10. Kaplan-Meier plot showing shorter time to first event in GISTs with 
infiltrative growth.  
 
Infiltrative growth tended to be more common (close to significant, P = 0.0503) among 
cases with metastasis at diagnosis: 10 out of 11 (91%) compared to 48 out of 79 (60%) 
without metastasis at diagnosis, Furthermore, a similar tendency was seen in a 
comparison between patients with infiltratively growing tumors with metastasis at 
diagnosis (10 of 11, 91%) and those who developed distant metastasis later during 
follow-up, 8 out of 14 (57%) (P = 0.062). This observation may indicate differences in 
mechanisms underlying early tumor progression but this needs further investigation. 
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5 CONCLUSIONS 
 
In the studies included in this thesis we aimed to identify specific molecular alterations 
associated with progressive disease and clinical evaluation has been done of the 
incidence and prognostic significance of adverse drug reactions, surgical margins and 
tumor growth pattern. 
 
Paper I 
Using immunohistochemical techniques and pathophysiological evaluation, we 
assessed 101 patients with highly malignant STS for known and suggested prognostic 
markers, particularly insulin-like growth factor type 1 receptor (IGF-1R). 
 
We concluded that in patients with highly malignant tumors (grade 3 or 4 on a four-
tailed scale), many of the already known prognostic markers, such as tumor size, 
necrosis, mitotic count, intralesional surgery, deep location and micro vascular density, 
were useful prognostic tools. However, malignancy grade 3 or 4 could not predict 
prognosis and neither could infiltrative growth pattern, vascular invasion, or any of the 
remaining immunohistochemical markers Ki67, p53, p27 and Bcl-2. 
 
Furthermore, we concluded that IGF-1R expression was a common feature in highly 
malignant STS, in our study associated with better survival and a low risk of 
developing metastases. These findings may suggest that IGF-1R and the IGF system 
are involved in malignant behavior of STS and may also provide a new prognostic tool 
in STS. 
 
Paper II 
Ezrin is a cytoskeleton protein involved in the growth and metastatic spread of cancer 
cells. We used immunohistochemical techniques to evaluate the prognostic role of the 
expression of ezrin in 50 patients with highly malignant STS from the same series as in 
Paper I. 
 
We found that ezrin expression was significantly associated with poor survival and the 
risk of developing metastatic disease. Ezrin may therefore be useful as an additional 
prognostic marker in highly malignant STS. 
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Paper III 
Imatinib, currently the first-line tyrosine kinase inhibitor (TKI) in advanced GIST, has 
led to a dramatically prolonged survival in advanced GIST. However, imatinib is 
associated with a lot of side effects. In a retrospective review of medical records from 
75 patients who had received imatinib, we analyzed the association between the 
occurrence of side effects and the outcome in patients with GIST. 
 
We found that moderate to severe or life-threatening side effects from imatinib were 
quite common and that the occurrence of adverse reactions might be associated with a 
better outcome. This indicates the importance of caring for patients with side effects so 
that they can manage them. Further investigation is needed into the correlation with 
plasma and intracellular concentrations. 
 
Paper IV 
In the last study, we analyzed the prognostic significance of surgical margins for 
GISTs. The extent of the resection margin was prospectively registered at the time of 
surgery or referral and the relation between resection margins and outcome was 
analyzed retrospectively. Margins were classified into wide, marginal or intralesional, 
as in other type of STSs.  
 
We found that a wide surgical margin is of significant prognostic importance, 
independent of both size and site of the tumor, suggesting its value as a prognostic 
marker and, most importantly, showing that precautions must be taken to obtain true 
free microscopic margins. 
 
Within the same cohort, we found the presence of a peripheral infiltrative growth 
pattern in more than half of the GISTs. Contrary to our expectations, we found no 
correlation between peripheral growth pattern and surgical margins. On the other hand, 
we did find that infiltrative growth was correlated to a higher risk of a first recurrent 
event, defined as local/peritoneal recurrence or metastasis, suggesting that the growth 
pattern has a role in the malignant behavior of GISTs.  
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